The $1M proceeds from the partnership with Define Biotech for Maitake mushroom dietary supplement production will directly benefit ABVC BioPharma's subsidiary BioKey. The expanded distribution in China and Taiwan will potentially increase the company's revenue and market presence. The growing global dietary supplements market, projected to reach $269.5B by 2030, further supports a positive short-term impact on ABVC's stock price.